Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Geneferon is a combination pharmaceutical product primarily used in the treatment of urogenital infections, including human papillomavirus (HPV) and cervical intraepithelial neoplasia (CIN). It consists of recombinant human interferon alfa-2b, which provides antiviral, immunomodulatory, and antiproliferative effects; taurine, which acts as an antioxidant and enhances tissue repair; and benzocaine, a local anesthetic that provides symptomatic relief. The drug is typically administered via vaginal or rectal suppositories. It has been studied in Kazakhstan and Russia as part of complex therapy for HPV-associated cervical diseases, often compared or combined with other modalities like photodynamic therapy. The product is designed to stimulate local immunity while providing direct antiviral activity and symptomatic comfort.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Geneferon.